Skip to main content

Table 2 Description of harm reduction services regularly provided by centres and number of users per centre (n = 11) during the first 6 months of the years 2019 and 2020, Spain (n = 11)

From: The impact of the COVID-19 pandemic on harm reduction services in Spain

Centre

(city name)

n. users 2019

(Jan–June)

n. users 2020

(Jan–June)

NSP

SIR

Naloxone distribution

Education services

Mental health services

OST

HCV DAA

HIV ART

HBV testing

HCV testing

HIV testing

TB testing

Centre 1 (Badalona)

265

274

✓

 

✓

✓

✓

       

Centre 2 (Bilbao)

923

721

✓

✓

 

✓

✓

    

✓

 

✓

Centre 3

(Madrid)

4528

1945

✓

 

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Centre 4

(Madrid)

892

1090

✓

 

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Centre 5

(Vitoria-Gasteiz)

77

60

✓

   

✓

✓

    

✓

 

Centre 6

(Bilbao)

1267

1080

✓

  

✓

✓

 

✓

✓

✓

✓

✓

 

Centre 7

(Reus)

394

398

✓

 

✓

✓

✓

✓

      

Centre 8

(Valencia)

764

687

✓

  

✓

✓

✓

✓

✓

✓

✓

✓

✓

Centre 9

(Bilbao)

1365

679

✓

  

✓

✓

       

Centre 10

(El Prat de Llobregat)

2652

3351

✓

 

✓

✓

✓

✓

 

✓

 

✓

✓

 

Centre 11

(Barcelona)

N/A

N/A

✓

✓

✓

✓

✓

 

✓

 

✓

✓

✓

✓

Centre 12

(Barcelona)

N/A

N/A

✓

✓

✓

✓

✓

✓

✓

 

✓

✓

✓

✓

Centre 13

(Sant AdriĂ  de Besos)

6166

3912

✓

✓

✓

✓

✓

 

✓

  

✓

✓

 

Total

  

13

4

8

12

13

7

7

5

6

9

9

6

  1. NSP Needle and syringe programme, SIR supervised injecting room, OST opioid substation therapy, DAA direct acting antivirals, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus (HIV), TB tuberculosis, N/A not available